Refractory autoimmune disease: An overview of when first-line therapy is not enough

Cindy E Neunert, Roula Farah, Joanne Yacobovich, Ellis Neufeld

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A recent Intercontinental Cooperative ITP Study Group (ICIS) meeting in September 2015 focused on immunomodulation across the spectrum of autoimmune conditions. It became clear to the attendees that in this wide range of conditions, there is a subset of patients that remain highly refractory to first line therapy. Therapeutic approaches to these patients vary greatly and while many different immunomodulatory agents have been investigated, few have seen universal success. We outline here the landscape of immunomodulation therapy for refractory patients across a variety of autoimmune conditions in order to highlight the variety of agents that have been studied, the lack of overall consensus about management, and the need for ongoing research in this area.

Original languageEnglish (US)
Article number50858
Pages (from-to)S35-S38
JournalSeminars in Hematology
Volume53
DOIs
StatePublished - Apr 1 2016

Fingerprint

Autoimmune Diseases
Immunomodulation
Inosine Triphosphate
Group Processes
Consensus
Therapeutics
Research

Keywords

  • Autoimmune disease
  • ITP
  • Immunomodulatory therapy

ASJC Scopus subject areas

  • Hematology

Cite this

Refractory autoimmune disease : An overview of when first-line therapy is not enough. / Neunert, Cindy E; Farah, Roula; Yacobovich, Joanne; Neufeld, Ellis.

In: Seminars in Hematology, Vol. 53, 50858, 01.04.2016, p. S35-S38.

Research output: Contribution to journalArticle

Neunert, Cindy E ; Farah, Roula ; Yacobovich, Joanne ; Neufeld, Ellis. / Refractory autoimmune disease : An overview of when first-line therapy is not enough. In: Seminars in Hematology. 2016 ; Vol. 53. pp. S35-S38.
@article{b7bc09f3612946c9927493c7da555847,
title = "Refractory autoimmune disease: An overview of when first-line therapy is not enough",
abstract = "A recent Intercontinental Cooperative ITP Study Group (ICIS) meeting in September 2015 focused on immunomodulation across the spectrum of autoimmune conditions. It became clear to the attendees that in this wide range of conditions, there is a subset of patients that remain highly refractory to first line therapy. Therapeutic approaches to these patients vary greatly and while many different immunomodulatory agents have been investigated, few have seen universal success. We outline here the landscape of immunomodulation therapy for refractory patients across a variety of autoimmune conditions in order to highlight the variety of agents that have been studied, the lack of overall consensus about management, and the need for ongoing research in this area.",
keywords = "Autoimmune disease, ITP, Immunomodulatory therapy",
author = "Neunert, {Cindy E} and Roula Farah and Joanne Yacobovich and Ellis Neufeld",
year = "2016",
month = "4",
day = "1",
doi = "10.1053/j.seminhematol.2016.04.011",
language = "English (US)",
volume = "53",
pages = "S35--S38",
journal = "Seminars in Hematology",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Refractory autoimmune disease

T2 - An overview of when first-line therapy is not enough

AU - Neunert, Cindy E

AU - Farah, Roula

AU - Yacobovich, Joanne

AU - Neufeld, Ellis

PY - 2016/4/1

Y1 - 2016/4/1

N2 - A recent Intercontinental Cooperative ITP Study Group (ICIS) meeting in September 2015 focused on immunomodulation across the spectrum of autoimmune conditions. It became clear to the attendees that in this wide range of conditions, there is a subset of patients that remain highly refractory to first line therapy. Therapeutic approaches to these patients vary greatly and while many different immunomodulatory agents have been investigated, few have seen universal success. We outline here the landscape of immunomodulation therapy for refractory patients across a variety of autoimmune conditions in order to highlight the variety of agents that have been studied, the lack of overall consensus about management, and the need for ongoing research in this area.

AB - A recent Intercontinental Cooperative ITP Study Group (ICIS) meeting in September 2015 focused on immunomodulation across the spectrum of autoimmune conditions. It became clear to the attendees that in this wide range of conditions, there is a subset of patients that remain highly refractory to first line therapy. Therapeutic approaches to these patients vary greatly and while many different immunomodulatory agents have been investigated, few have seen universal success. We outline here the landscape of immunomodulation therapy for refractory patients across a variety of autoimmune conditions in order to highlight the variety of agents that have been studied, the lack of overall consensus about management, and the need for ongoing research in this area.

KW - Autoimmune disease

KW - ITP

KW - Immunomodulatory therapy

UR - http://www.scopus.com/inward/record.url?scp=84973855840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973855840&partnerID=8YFLogxK

U2 - 10.1053/j.seminhematol.2016.04.011

DO - 10.1053/j.seminhematol.2016.04.011

M3 - Article

C2 - 27312162

AN - SCOPUS:84973855840

VL - 53

SP - S35-S38

JO - Seminars in Hematology

JF - Seminars in Hematology

SN - 0037-1963

M1 - 50858

ER -